BioCentury
ARTICLE | Clinical News

QuatRx becocalcidiol Phase IIb psoriasis data

June 15, 2005 1:34 AM UTC

QuatRx (Ann Arbor, Mich.) said two doses of becocalcidiol ( QRX-101) met the primary endpoint of "clear" or "almost clear" of psoriatic lesions at eight weeks compared with vehicle in a Phase IIb tria...